(2026). Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: A real-world observational study. PeerJ.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Impact of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors on Intracranial Atherosclerotic Plaque Characteristics and Low Density Lipoprotein-cholesterol (LDL-C) Reduction: A Real-world Observational Study."
PeerJ 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Impact of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors on Intracranial Atherosclerotic Plaque Characteristics and Low Density Lipoprotein-cholesterol (LDL-C) Reduction: A Real-world Observational Study."
PeerJ, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.